BiotechTube

TA103 + Placebo Control

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tinea Pedis

Conditions

Tinea Pedis

Trial Timeline

Sep 3, 2020 → Feb 20, 2021

NCT ID
NCT04883593

About TA103 + Placebo Control

TA103 + Placebo Control is a phase 1 stage product being developed by Sun Pharmaceutical for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT04883593. Target conditions include Tinea Pedis.

What happened to similar drugs?

3 of 11 similar drugs in Tinea Pedis were approved

Approved (3) Terminated (1) Active (7)
🔄Sertaconazole nitrate cream 2%Johnson & JohnsonPhase 3
❌Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)Johnson & JohnsonPhase 3
🔄Terbinafine hydrochloride (HCl) + GriseofulvinNovartisPhase 3
🔄Terbinafine + Terbinafine PlaceboNovartisPhase 3
🔄Terbinafine hydrochlorideNovartisPhase 3
🔄fluconazolePfizerPhase 3
🔄Econazole Nitrate Cream, 1% + PlaceboViatrisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04883593Phase 1Completed

Competing Products

20 competing products in Tinea Pedis

See all competitors
ProductCompanyStageHype Score
Butenafine Hydrochloride 1% + Butenafine Hydrochloride 1% B + Butenafine Hydrochloride 1% + Vehicle A + Vehicle BSun PharmaceuticalPhase 1
21
Naftifine Hydrochloride Gel 2% + Naftin® Gel 2% + Placebo Topical GelSun PharmaceuticalPhase 1
29
Naftifine Hydrochloride Cream 2% + Naftin® (Naftifine Hydrochloride) Cream 2% + Placebo Topical CreamSun PharmaceuticalPhase 1
29
Butenafine Hydrochloride Cream, 1% + Lotrimin Ultra® + Butenafine VehicleSun PharmaceuticalPhase 1
29
Naftifine HCl Cream 1% + Naftin® (Naftifine HCl) Cream 1% + Placebo topical creamSun PharmaceuticalPhase 1
29
Ketoconazole Shampoo, 2% + Ketoconazole Shampoo, 2% (Reference Standard) + PlaceboSun PharmaceuticalPhase 1
29
Oxiconazole Nitrate Cream 1% + Oxiconazole Nitrate Cream 1% (Oxistat®) + PlaceboSun PharmaceuticalPhase 1
29
Butenafine cream 1% manufactured by Taro + Lotrimin Ultra (butenafine) 1% + Butenafine Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Sertaconazole nitrate cream 2%Johnson & JohnsonPhase 3
36
Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)Johnson & JohnsonPhase 3
32
Terbinafine hydrochloride (HCl) + GriseofulvinNovartisPhase 3
40
Terbinafine + Terbinafine PlaceboNovartisPhase 3
40
Terbinafine hydrochlorideNovartisPhase 3
40
fluconazolePfizerPhase 3
40
AN2718 + AN2718 + AN2718 + AN2718 + AN2718 + AN2718PfizerPhase 1
29
W0027 + PlaceboGSK plcPhase 1
29
Bifonazole spray once daily + Bifonazole spray twice daily + Placebo + Placebo + Lamisil OnceBayerPhase 2
32
Econazole Nitrate Cream, 1% + PlaceboViatrisPhase 3
37
LAS41003 + LAS189961 + LAS189962AlmirallPhase 2
29
Luliconazole Cream 1% + Vehicle CreamBausch HealthApproved
37